Supplementary material for A study of ultra-low dose rituximab as adjuvant to standard of care in treatment of significant and extensive pemphigus vulgaris: a case series

Description

Supplementary material contains two figures. Figure 1 shows recruitment data for the study and figure 2 depicts graph showing absolute CD19 cell count before and after rituximab therapy. Text after the figures explains PDAI-classification of pemphigus vulgaris disease severity.

Categories

Licence